Health Hearing: Policies to Protect Our Communities from Illicit Drug Threats

The House Committee on Energy and Commerce held a health hearing on March 27, 2026, focused on policies to protect communities from illicit drug threats, particularly synthetic opioids and emerging substances like xylazine and nitazenes. The hearing reviewed 14 bills aimed at scheduling new substances under the Controlled Substances Act, regulating illicit pill presses, enhancing data collection on opioid use disorder, and expanding access to non-opioid pain management. Witnesses, including law enforcement officials, veterinary experts, addiction medicine physicians, and researchers, testified on the evolving drug landscape, the importance of balanced scheduling to preserve legitimate veterinary and medical uses, and the need for improved forensic and wastewater testing to detect emerging threats. Several members expressed concern about recent federal funding cuts to substance use disorder programs and the potential negative impact of Medicaid restrictions on treatment access. The hearing also discussed the importance of maintaining and expanding medication-assisted treatment and the challenges posed by counterfeit pills laced with fentanyl and other substances. No votes were taken during the hearing, but members indicated ongoing efforts to refine legislation addressing both supply and demand aspects of the opioid crisis.